E-Commerce Law Reports: PATENTS: A reverse payment agreement between a generic drugs manufacturer having filed a paragraph IV certification to produce a generic form of a patented drug, with the pioneer manufacturer, does not violate U.S. antitrust laws.

June.01.2012